Insulin-like growth factor 1 gene (CA)n repeats and a variable number of tandem repeats of the insulin gene in Brazilian children born small for gestational age by Coletta, Rocio R.D. et al.
Insulin-like growth factor 1 gene (CA)n repeats and a
variable number of tandem repeats of the insulin
gene in Brazilian children born small for gestational
age
Rocio R. D. Coletta,I Alexander A. L. Jorge,I Catarina Brasil D’ Alva,I Emı´lia M. Pinto,I Ana Elisa C. Billerbeck,I
Paulo R. Pachi,II Carlos A. Longui,III Ricardo M. Garcia,III Margaret Boguszewski,IV Ivo J. P. Arnhold,I
Berenice B. Mendonca,I Elaine M. F. CostaI
IHospital das Clı´nicas da Faculdade de Medicina da Universidade de Sa˜o Paulo, Unidade de Endocrinologia do Desenvolvimento, Laborato´rio de
Hormonios e Genetica Molecular LIM/42, Sa˜o Paulo/SP, Brazil. II Santa Casa de Sa˜o Paulo, Ambulato´rio de Seguimento de Prematuros, Sa˜o Paulo/SP, Brazil.
III Santa Casa de Miserico´rdia de Sa˜o Paulo, Unidade de Endocrinologia Pedia´trica, Sa˜o Paulo/SP, Brazil. IVHospital de Clı´nicas de Curitiba, Unidade
Endocrinologia Pedia´trica, Curitiba/PR, Brazil.
OBJECTIVE: To investigate the influence of (CA)n repeats in the insulin-like growth factor 1 gene and a variable
number of tandem repeats of the insulin gene on birth size in children who are small or adequate-sized for
gestational age and to correlate these polymorphisms with serum insulin-like growth factor 1 levels and insulin
sensitivity in children who are small for gestational age, with and without catch-up growth.
PATIENTS AND METHODS: We evaluated 439 infants: 297 that were adequate-sized for gestational age and 142
that were small for gestational age (66 with and 76 without catch-up). The number of (CA)n repeat in the
insulin-like growth factor 1 gene and a variable number of tandem repeats in the insulin gene were analyzed
using GENESCAN software and polymerase chain reaction followed by enzymatic digestion, respectively.
Clinical and laboratory data were obtained from all patients.
RESULTS: The height, body mass index, paternal height, target height and insulin-like growth factor 1 serum
levels were higher in children who were small for gestational age with catch-up. There was no difference in the
allelic and genotypic distributions of both polymorphisms between the adequate-sized and small infants or
among small infants with and without catch-up. Similarly, the polymorphisms were not associated with clinical
or laboratory variables.
CONCLUSION: Polymorphisms of the (CA)n repeats of the insulin-like growth factor 1 gene and a variable
number of tandem repeats of the insulin gene, separately or in combination, did not influence pre- or postnatal
growth, insulin-like growth factor 1 serum levels or insulin resistance.
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Gene; Growth.
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& INTRODUCTION
Several endocrine and environmental factors have been
implicated in fetal growth. Among the endocrine factors, the
insulin and the insulin-like growth factor systems have a
critical role in mediating pre- and postnatal growth. Their
strong stimulatory effect on growth is supported by the
observation of marked pre- and postnatal growth failure in
Igf1 or insulin knock-out animal models (1) and in humans
with IGF1 gene defects (2–4).
The substantial contribution of genetic factors to the inter-
individual variation in circulating IGF-1 levels is well
recognized (5). Lower circulating IGF-1 levels have been
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observed in children that present with intrauterine growth
retardation (6–8). Because there are few reports of mutations
in the IGF1 gene in children born small for gestational age
(SGA) (2-4), associations between growth and polymorph-
isms in the non-coding regions of IGF1, which may affect
transcription or messenger RNA processing, have been
analyzed. (9,10).
59-(CA)n repeats in the IGF1 gene are common and are the
most-investigated polymorphism in association studies.
(CA)n repeats in the IGF1 gene comprise a microsatellite
characterized by a variable number of CA repeats (10 to 24)
in the promoter region of the IGF1 gene (Genbank accession
number: M12659, data base: UniSTS); this polymorphism is
characterized by alleles ranging in length from 174–202 bp
that start 947 bp upstream from the initiation site (11–17).
As summarized in Table 1, the involvement of the wild-type
192-bp allele (19 CA repeats) in clinical disorders, birth size
and IGF1 serum levels is still controversial in the literature
(9,10,14,16–19).
IGF1 secretion and prenatal growth are regulated by the
glucose-insulin-IGF1 axis. The placenta transfers glucose to
the fetus, thereby stimulating the secretion of fetal insulin,
which determines the amount of IGF1 secretion (20). In
postnatal life, growth hormone is the main regulator of IGF1
expression; however, in the prenatal period, growth
hormone exerts little influence on fetal growth.
The VNTR (variable number of tandem repeats) of the
insulin gene (INS VNTR) consists of repetitions of the
variable oligonucleotide ACAGGGGT(G/C)(T/C)GGGG
and is located 596 bp upstream of the transcript starting
codon. According to the number of repetitions, the alleles
can be divided into: class I alleles with 26 to 63 repetitions
(approximately 570 bp), class II alleles with 64 to 140
repetitions (approximately 1,200 bp) and class III alleles
with 141 to 209 repetitions (approximately 2,200 bp) (21).
The variation in the INS VNTR length regulates the
transcription of the insulin gene and the contiguous IGF2
gene (22). Similarly to the (CA)n repeats, the association of
the INS VNTR with low birth weight and insulin resistance
syndrome is controversial; the research on this topic is
summarized in Table 2.
It is worth noting that 90% of children who are born SGA
achieve a normal weight and length during the first two
years of life (9,23). However, SGA without postnatal catch-
up is a clinically complex entity and most likely has a
polygenic etiology. For this reason, the aim of the present
study was to analyze two polymorphisms, i.e., (CA)n
repeats in the IGF1 gene and the INS VNTR of the insulin
gene, separately or in combination, in relation to birth size
and catch-up growth in Brazilian children born adequately
sized for gestational age (AGA) and SGA. Additionally, we
compared these polymorphisms with IGF1 serum levels and
insulin sensitivity in SGA children with and without catch-
up growth.
& PATIENTS AND METHODS
Patients
The study was approved by the local research ethical
committee, and informed written consent was obtained
from all patients’ parents or guardians. Information con-
cerning health status, birth weight, birth length, birth head
circumference, gestational age and maternal conditions
during the pregnancy (e.g., previous or gestational diabetes
mellitus and smoking) were ascertained by reviewing the
patients’ medical records. The anthropometric data were
expressed as standard deviation scores (SDS) adjusted for
sex and gestational age (24). We evaluated 439 infants over 2
years of age from three different Brazilian centers; these
infants were divided into two groups, i.e., born small for
gestational age (SGA group) or adequate for gestational age
(AGA group), according to their birth length and birth
weight SDS (25,26). The AGA group consisted of 297
children whose birth length and birth weight SDS were
,22.0, and the SGA group consisted of 142 children whose
birth length and/or birth weight SDS were $22.0. None of
these children showed signs of severe hypoxia in the
neonatal period (defined as a 5-minute Apgar score ,6).
Additionally, the SGA group was divided into two
subgroups according to height after two years of age: one
group contained 66 children with catch-up growth (height
SDS ,22), whereas the other group contained 76 children
without catch-up growth (height SDS $22) (27).
Children with endocrine or metabolic disorders, chromo-
somal defects, genetic syndromes (except Silver Russell
syndrome) or growth failure caused by other conditions
(e.g., malnutrition, emotional deprivation, severe chronic
illness and chondrodysplasia) were excluded.
Biochemical measurements
Serum IGF1 levels were measured in the SGA children
using a specific immunoradiometric assay (IRMA) or
Table 1 - Relevant studies associating promoter IGF1 59-(CA)n repeats with clinical disorders, birth size and IGF1 serum
levels.
Population N (CA)n repeats Results References
Adults 900 192 bp non-carriers QIGF1 serum levels, lower final height, higher
risk of type 2 diabetes and myocardial infarction
Vaessen et al., 2001 (17)
AGA Adults 463 192 bp non-carriers Lower birth weight Vaessen et al., 2002 (18)
Adults 171 192 bp carriers QIGF1 serum levels and osteoporosis in men Rosen et al.,1998 (16)
AGA Adults 640 192 bp carriers QIGF1 serum levels and no association
with type 2 diabetes and birth weight
Frayling et al., 2002 (14)
AGA Children 738 192 bp non-carriers Association with smaller fetal size, followed by
qgrowth from mid-pregnancy to early infancy
Geelhoed et al., 2008 (19)
Short Stature SGA Children 124 198 bp carriers Minimal transmission from parents to SGA children Arends et al., 2002 (9)
SGA 174 198 bp carriers S-SGA only in Swedish population. No
association with IGF1 serum levels
Johnston et al., 2003 (10)
Short Stature SGA Children 201 192 bp carriers No association with birth size and post-natal growth Ester et al., 2009 (46)
SGA and AGA Infants 142/297 192 bp non-carriers No association with birth size and IGF1 serum levels Present study
SGA: small for gestational age; AGA: adequate size for gestational age; Q: decreased; S-SGA: short-small for gestational age.
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enzyme-labeled chemiluminescent immunometric assay
(ICMA) (28,29), and the values were transformed into SDS
adjusted for sex and age. Blood glucose levels were
determined by the enzymatic colorimetric method (glu-
cose-oxidase) (30). Insulin levels were determined by an
immunofluorometric assay (IFMA) (31,32). Insulin resis-
tance was determined using the HOMA-IR index (fasting
insulin (mU/ml) 6 fasting plasma glucose (mmol/l)/22.5)
(33).
Molecular analysis
Genomic DNA from peripheral blood lymphocytes was
amplified by polymerase chain reaction (PCR) with specific
primers for the region containing the polymorphic promoter
cytosine-adenine [(CA)n] repeats, which are located
approximately 1 kb upstream of the human IGF1 gene (9).
The PCR reaction was performed in a final volume of 25 ml
containing 50 ng of genomic DNA, 0.5 nmol of each primer,
1.5 mM MgCl2, 250 mM dNTP and 2.5U of Taq DNA
polymerase (InvitrogenH). After the initial denaturation for
10 min at 94 C˚, the samples were subjected to 25 cycles of 30
seconds at 94 C˚, 30 seconds at 55 C˚ and 30 seconds at 72 C˚;
these cycles were followed by a final extension step of 10
minutes at 72 C˚. The forward primers were labeled with
FAM, which is a fluorescent size marker, to determine the
size of PCR products using an autosequencer (ABI Prism
3100 Genetic analyzer); this size determination was fol-
lowed by analysis with GENESCAN Fragment Analysis
software (Applied Biosystems, Foster City, CA, USA).
The INS VNTR polymorphisms were analyzed by PCR
and enzymatic digestion. The INS-23 A/T polymorphism,
which is located in the promoter region of the insulin gene,
is in linkage disequilibrium with INS VNTR classes I and III.
Adenine (A) indicates the presence of the class I allele,
wheras thymine (T) indicates the presence of the class III
allele (34). A 360 bp region containing this polymorphism
was amplified using 200 ng of genomic DNA, 2.5 U of Taq
DNA polymerase (Promega H), 6.7 mM MgCl2, 200 mM
dNTP, 200 ng of the INS VNTR-specific primers sense 5
9AGCAGGTCTGTTCCAAGG 39 and antisense-INS VNTR 5
9CTTGGGTGTGTAGAAGAAGC 39 and 2.5 U of Taq DNA
polymerase (Promega H), in a final volume of 50 mL. The
PCR conditions were: 96˚ C for 12 minutes; 35 cycles
consisting of 94 C˚ for 1 minute, 54 C˚ for 1 minute and 72 C˚
for 45 seconds; and 10 minutes at 72 C˚ for the final extension
step.
The PCR products were digested using the restriction
enzyme Hph1 (New England Biolabs H) according to the
manufacturer’s instructions (34) and subjected to 3%
agarose gel electrophoresis. If thymine is present, the
enzyme cuts the region into two fragments with lengths of
231 and 129 bp; if adenine is present, three fragments are
produced with lengths to 191 bp, 129 bp and 40 bp. These
groups of fragments correspond to the class III and class I
alleles, respectively.
All samples were amplified in a GeneAmp PCR
Instrument System 9600 automatic thermocycler (Perkin-
Elmer/Cetus, Norwalk, CT, USA), and all amplifications
were accompanied by a negative control.
Statistical analysis
The Hardy-Weinberg equilibrium of the IGF1 and insulin
promoter polymorphism genotypes was tested, and the
allele and genotype frequencies were all in Hardy-Weinberg
equilibrium. The data were expressed as the mean¡SD.
Birth length, birth weight, head circumference, height and
IGF1 levels were expressed as SDS. In addition, glucose,
insulin and HOMA-IR were analyzed in combination with
the clinical variables. Cross tabulation paired with the Chi-
Squared Test or Fisher Exact Test was used to analyze
categorical data; a t-Test or ANOVA was used for
comparisons of the mean between normally distributed
variables; and the Mann-Whitney or Kruskal-Wallis test was
used for comparisons among skewed variables. A p,0.05
was considered statistically significant.
To verify the correlation between dependent and inde-
pendent variables, a logistic regression analysis (not linear)
was used for binary dependent variables, and a linear
regression analysis was used for numerical variables.
Spearman’s correlation was used for the selection of
independent variables with a significance of p,0.20.
All analyses were performed using the SPSS program
(Statistical Package Social Sciences graph), Version 13.0, and
the threshold for statistical significance was p,0.05.
& RESULTS
Clinical results
All children from the AGA group presented with normal
birth weight (0.5¡1.2 SDS) and length (20.5¡1.1 SDS).
The clinical data for the SGA groups with and without
catch-up growth are displayed in Table 3. The birth weight
and length SDS were similar between the SGA groups.
Children with catch-up, however, presented with signifi-
cantly higher height, target height (TH) and BMI (index
body mass) SDS than those without catch-up growth
(p,0.05). Unexpectedly, the head circumference was smaller
in children with catch-up.
Table 2 - Relevant studies associating promoter INS VNTR of the insulin gene with anthropometric data and clinical
disorders.
Studied Population n INS VNTR Associations References
AGA Children 758 I/I QBirth weight, without catch-up growth Dunger et al., 1998 (47)
AGA Girls 141 Allele I QBirth weight, higher HOMA-IR Iba´n˜ez et al., 2001 (50)
AGA Men 105 III/III QBirth weight, without catch-up growth, DM2 Ong et al., 1999 (48)
AGA Pima Indians 660 Allele III QBirth weight, DM2 Lindsay et al., 2003 (49)
AGA 5646 Allele I and III No association with birth size and insulin resistance Mitchell et al., 2004 (34)
SGA and AGA Children 735/886 Allele I and III No association with birth size Vu-Hong et al., 2006 (52)
Allele III Higher insulin resistance in SGA children
SGA and AGA Infants 439 Allele I and III No association with birth size and insulin resistance Present study
SGA: small for gestational age; AGA: adequate size for gestational age; Q: decreased; S-SGA: short-small for gestational age; DM2: type 2 diabetes
mellitus.
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In the laboratory analysis, serum IGF1 levels were
significantly higher in the SGA catch-up group than in the
SGA group without catch-up. Although the mean insulin
serum concentration and HOMA-IR index were higher in
SGA children with catch-up growth, the difference was not
statistically significant.
The frequency of maternal smoking during pregnancy
was significantly higher in SGA children who had catch-up
growth (p,0.05). The frequency of gestational or previous
diabetes mellitus was similar in both SGA groups.
Logistic regression analysis revealed that the highest
probability of catch-up growth (99.93%) was related to the
maximal values of independent variables, such as the height
SDS of the father and the IGF1 SDS. Linear regression
analysis demonstrated a lack of influence of any of the clinical
variables analyzed on the height SDS and the IGF1 SDS.
Molecular results
The molecular results are displayed in Table 4. The length
of the PCR products that contained the IGF1 59-(CA)n
repeats ranged from 184 to 204 bp in our cohort, and the
PCR products represented nine distinct alleles. The 192-bp
allele was the most common in our population and was
found in three different genotypic groups: children who
were homozygous for the 192-bp allele (192/192), children
who were heterozygous for the 192-bp allele (192/*) and
children who did not carry the 192-bp allele (*/*). There was
no difference in the allelic and genotypic frequency of IGF1
59- (CA)n repeats between the AGA and SGA groups.
With regard to the distribution and frequency of the INS
VNTR class I and III alleles, no difference was found in the
allelic and genotypic distribution between the AGA and
SGA groups or between the SGA groups with and without
catch-up. Similarly, this polymorphism was not associated
with the clinical and laboratory variables analyzed in this
study. In addition, the IGF1 (CA)n repeats and the INS
VNTR were not related to pre- and postnatal growth;
furthermore, there was no association between these
polymorphisms and serum IGF1 levels or insulin resistance
in our cohort of individuals born SGA.
& DISCUSSION
Intrauterine and postnatal growth, as well as height, are
complex clinical traits that are influenced by many genes.
This study showed that the parents, particularly fathers,
of children SGA without catch-up growth were significantly
shorter than those of children SGA with catch-up. Our
findings suggest that the genetic factors that determine
permanent short stature in children born SGA are mainly of
paternal origin; this phenomenon has been previously
described in the literature (46).
Ong et al. (35) demonstrated that catch-up growth in the
first two years of life is a risk factor for central obesity in
childhood. Similarly, we observed that the BMI SDS was
higher in children with catch-up growth, which indicates
that these children must be followed until adult age to
prevent the onset of obesity and future co-morbidities.
Gluckman et al. (20) demonstrated that birth size is
directly correlated with serum concentrations of IGF1 in the
umbilical cord, which in turn are directly influenced by the
nutritional status of the fetus. In addition, Gluckman et al.
observed that serum concentrations of IGF1 during the first
year of life in children born SGA are positively associated
with catch-up growth and may reflect insulin secretory
capacity (36). Therefore, higher serum concentrations of
IGF1 in SGA children with spontaneous catch-up may be an
indicator of relative resistance to insulin and IGF1 and may
constitute an increased risk for the onset of Type 2 diabetes
mellitus in adulthood. We also found higher IGF1 serum
concentrations in children born SGA with catch-up growth,
Table 3 - Clinical data of children born small (SGA) for gestational age with and without catch–up growth.
Data Catch-up growth n = 142 p-value
Catch-up(n = 66) Mean ¡ SD No catch-up (n = 76) Mean ¡ SD
Birth weight SDS 22.47¡0.85 22.33¡1.07 NS
Birth length SDS 23.45¡1.16 23.42¡1.28 NS
Head circumference SDS 22.25¡1.28 21.22¡1.47 ,0.05
Height SDS (2–4 years) 20.58¡0,83 23.14¡1 ,0.05
Target height SDS 20.72¡0.98 21.21¡0.94 ,0.05
BMI SDS 20.29¡1.71 21.16¡1.56 ,0.05
IGF1 SDS (2–4 years) 0.032¡1.44 20.86¡1.26 ,0.05
Glucose 81.25¡10.22 81.61¡7.11 NS
Insulin 6.32¡5.35 4.45¡0.70 NS
HOMA-IR 1.32¡1.15 0.91¡0.68 NS
SGA: small for gestational age; Z-BMI: body mass index HOMA-IR: index of insulin resistance; NS: non-significant.
Table 4 - Genotype frequency of IGF1 59-(CA)n repeats and INS VNTR of the insulin gene in the SGA and AGA groups.
Polymorphism Genotype SGA = 142 Total n (%) AGA = 297 Total n (%) p-value
(CA)n IGF1 192/192 41 (29) 83 (28) NS
192/* 76 (54) 163 (55) NS
*/* 25 (17) 51 (17) NS
INS VNTR I/I 45 (32) 101 (34) NS
III/III 40 (28) 48 (16) NS
I/III 57 (40) 148 (50) NS
SGA: small for gestational age; AGA: adequate size for gestational age; NS: non-significant (p.0.05).
IGF1 gene (CA)n repeats and INS VNTR in SGA children
Coletta RR et al.
CLINICS 2013;68(6):785-791
788
but the insulin levels were similar in SGA individuals with
and without catch-up growth.
In the last few decades, several studies have demon-
strated a higher frequency of insulin resistance in children
and adults born SGA (37-42). Soto et al. (43) showed higher
insulin resistance in children born SGA who had catch-up
growth. Although their results are controversial, other
studies have also indicated that low birth weight is
associated with an increased risk of insulin resistance
syndrome when accompanied by stature recovery, which
strengthens the evidence that nongenetic mechanisms
determine insulin resistance and low birth weight. If insulin
resistance syndrome is multifactorial in origin, the INS
VNTR may represent a genetic risk factor. In this study,
insulin sensitivity, as measured by the HOMA-IR index,
was slightly higher in subjects born SGA with catch-up
growth, but this correlation did not reach significance, most
likely because of the small number of children involved in
the present study and their chronological age (they are very
young). It is possible that if these children are analyzed in
the future, an association may be observed between insulin
resistance and these polymorphisms.
Among maternal causes of SGA, smoking is one of the
most common preventable causes of intrauterine growth
retardation (23). Newborns born to smoking mothers
generally have lower weight, length and head circumfer-
ence at birth (44,45). We observed that the incidence of
maternal smoking was higher in SGA children with catch-
up growth, which suggests that in postnatal life, outside of
the hostile intrauterine environment, these children will
express their genetic potential for growth.
Because of the crucial role of IGF1 in pre- and postnatal
growth, some studies have addressed the influence of IGF1
59-(CA)n repeats on birth length and weight as well as child
growth. The 192-bp allele of IGF1 (CA)n repeats has been
found in the homozygous and heterozygous states in 37 –
47% and 42 – 49% of UK and Dutch populations,
respectively (14,17). A similar frequency was observed in
our cohort, despite the high miscegenation that is found in
the Brazilian population.
59-(CA)n repeats in IGF1 were first reported in a study
that investigated the influence of IGF1 gene polymorphisms
on serum IGF1 levels and bone mineral density in a small
group of adult patients. In this first report, adults homo-
zygous for the 192-bp allele presented with lower IGF1
levels and BMD (body mass density) relative to those with
other (CA)n genotypes (16). However, in a subsequent
study that evaluated this polymorphism in a large group of
diabetic patients and controls, the presence of the 192-bp
allele was associated with higher IGF1 levels as well as an
increase in height. Additionally, non-carriers of the 192-bp
allele presented with an increased relative risk for type 2
diabetes and myocardial infarction (17). In contrast, some
studies of adults born AGA showed an association of the
wild-type allele (192) with low IGF1 circulating levels and a
lack of correlation between the 192-bp allele and weight,
height and head circumference SDS at birth (14,16).
AGA children who are non-carriers of the 192-bp allele
tend to have a smaller fetal size during gestation, followed
by increased growth from mid-pregnancy to early infancy
(19); the birth weight of these children was also shown to be
215 g lower than that of individuals who were homozygous
for this allele (Table 1). In another study, four IGF1 gene
polymorphisms were analyzed in 201 short-SGA children
(46), and no association of CA repeats with birth size or
postnatal growth was observed (Table 1).
Regarding children born SGA, only three studies (9,10,46),
all from the same research group, have assessed the
influence of IGF1 59-(CA)n repeats in pre- and postnatal
growth parameters in children from two distinct Caucasian
populations (Sweden and the Netherlands). In the first
study, transmission disequilibrium of the 198-bp allele was
observed; this allele was transmitted less frequently from
parent to child. Because of the low frequency of this allele
(0.4%), this result should be cautiously considered (9). In a
subsequent study, Johnston et al. (11) demonstrated the
association of a haplotype that combined the 198-bp allele of
IGF1 59-(CA)n repeats and another IGF1 promoter SNP (T-
1148C) with the short SGA phenotype. Finally, another
haplotype, which combined the 192-bp allele of the IGF1 59-
(CA)n repeats and the G1245A SNP, was associated with a
smaller head circumference SDS during spontaneous post-
natal growth, but not during growth hormone (GH)
treatment. In addition, no associations were found with
birth size and postnatal growth (46).
In the present study, we screened AGA and SGA patients
for the IGF1 59-(CA)n repeat polymorphism, and no
association with birth size or birth length was found. In
our SGA children, we also failed to find an association of the
IGF1 59-(CA)n repeats with birth size, the presence or
absence of catch-up growth and IGF1 serum levels.
The absence of functional studies* regarding IGF1 59-
(CA)n repeats raises the question of whether this poly-
morphism itself participates in the regulation of IGF-I
expression or merely flags another polymorphism in the
promoter region that is functionally involved in IGF1
expression.
It is known that insulin is a relevant endocrine factor that
determines fetal growth. However, most studies correlating
the INS VNTR (genotypes or allele class I or III) with low
birth weight, insulin resistance and absence of catch-up
growth were conducted in subjects born with a size
adequate for their gestational age (47,34,48–50) (Table 2).
Some of these studies analyzed the relationship of birth size
with insulin resistance and found no association of alleles I
and III of the INS VNTR with birth size (34,51–53).
However, Mitchell et al. (34) described an association of
the class III allele with increased insulin resistance (Table 2).
Maas et al. (54) studied the INS VNTR and CA repeats of the
IGF1 gene in AGA children but did not find interactions
between these genotypes and birth weight or measures of
body composition. Only one study (52) comparing subjects
born SGA and AGA showed higher insulin resistance in
individuals who carried allele III, but there was no
association of the INS VNTR with birth size (Table 2).
In the present study, we confirmed a lack of association of
the INS VNTR with birth size, postnatal growth or the
presence of insulin resistance.
When analyzing the two polymorphisms, i.e., the INS
VNTR and IGF1 (CA)n repeats, in combination, we failed to
find any association with birth size in the SGA group, as
previously demonstrated in AGA children (54).
Studies correlating IGF1 59-(CA)n repeats and INS VNTR
polymorphisms with growth, IGF1 serum levels and insulin
sensitivity are controversial independently of the popula-
tion characteristics (children or adults born SGA or AGA).
Various reasons might explain the discrepancies observed
among these studies (55–57): 1) false-positive results caused
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by multiple testing (type 1 error); 2) false-negative results
caused by insufficient power (type 2 error); 3) population
stratification; 4) or finally, a real difference between studied
populations. Similarly, in this study, it was not possible to
eliminate these biases.
Therefore, further studies are needed to establish an
association of IGF1 59-(CA)n repeats and INS VNTR with
fetal growth. Furthermore, a meta-analysis and/or func-
tional studies* will be able to confirm the relevant role of
these polymorphisms in pre- and postnatal growth, as well
as their association with the serum IGF1 levels.
In conclusion, by comparing SGA children with and
without catch-up growth and AGA children, this study
demonstrates for the first time that IGF1 (CA)n repeats and
INS VNTR separately or in combination do not influence
birth size, postnatal growth, IGF1 serum levels and insulin
resistance. The young age of the patients in this study may
explain why we failed to find any association with insulin
levels.
*An ‘‘in vitro’’ or functional study is a molecular tool used
to demonstrate the effect of a mutation or polymorphism on
gene function.
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